Figure 6. Enhanced anticancer effects.

In vivo cancer treatment and theranostic tumor imaging in nude mice (9–11 weeks, both sexes) bearing Raji lymphoma tumors with the initial volume of 600–800 mm³: (A) Tumor inhibition curves and (B) body weight changes of mice after intravenous treatment with G2 and G3 nanoformulations of DOX at 10 and 15 mg/kg, respectively, for three doses on day 0, 4, 8 (n = 5–7). PBS injection was used in the control group. (C) In vivo volume and ex vivo weight of tumors in the G2 and G3 treatment groups. (D) In vivo NIRF optical images of Raji lymphoma bearing mice #5 treated with the intravenous injection of DiD-DOX-coloaded G3 PEG^5kCA₄-L-Rh₄ micelles (10 mg/kg) for three times on days 0, 4, 8. (E) Fluorescent quantitative tumor uptake analysis and (F) tumor volume measurements of individual mice in the G3 DiD-DOX treatment group. (G) Lymphoma tumor tissue #2L and #3 stained with DAPI and observed under fluorescent confocal microscope: Red fluorescent is the signal from DiD and nuclei are in blue. Scale bar: 20 μm.